AstraZeneca’s Tagrisso maintains momentum in NSCLC with FLAURA2 results

Lung cancer is the leading cause of cancer death around the world, with an estimated 2.2 million new cases and 1.8 million lung cancer-related deaths per year.

Non-small cell lung cancer (NSCLC) constitutes around 85% of lung cancer cases, with a further 15-20% of patients afflicted by epidermal growth factor receptor mutations (EGFRm).